Non-alcoholic fatty liver disease is emerging as a major cause of liver cancer, according to data from a new study presented at the annual meeting of the European Society for the Study of the Liver (EASL) on April 24, 2015.Given the prevalence of this type of liver disease, the burden of disease-related complications is expected to rise, Dr. Younossi said at the meeting. According to statistics, from 2004 to 2009, the annual increase in liver cancer in patients with fatty liver was about 5 percent. The survival period of patients with fatty liver with cancer is shorter than that of patients with hepatitis B and C with liver cancer. Usually, clinical symptoms appear at an advanced stage and patients are unable to undergo liver transplantation because of comorbidities. What is more concerning is that patients with fatty liver may not realize that patients with advanced fibrosis are at a higher risk of developing liver cancer, and Dr. Younossi believes that this group of patients may have non-alcoholic steatohepatitis, and that the only way to confirm the diagnosis of this disease is with a liver biopsy, which, because it is invasive and can only be done by a small number of people, has not yet been diagnosed in a large number of patients with non-alcoholic steatohepatitis. It is also recommended that patients with fatty liver be checked regularly to see if liver fibrosis has occurred. If they do, they should be screened for liver cancer every 6 months. Statistics show that liver cancer is associated with 48% of hepatitis C, 26% of fatty liver, 14% of alcoholic liver disease, 8% of hepatitis B, and 4% of cases of autoimmune hepatitis or biliary cirrhosis. The percentage of liver cancer associated with fatty liver is second only to the percentage of liver cancer associated with hepatitis C. The prevention and treatment of fatty liver has to attract the attention of all sectors of society. Currently, there are no effective therapeutic drugs for patients with fatty liver, except for dietary modification, moderate aerobic exercise, and correction of poor lifestyle and behavior. Liver fibrosis is the only reversible pathological stage in the progression of all chronic liver diseases, including fatty liver, into end-stage liver diseases such as cirrhosis and hepatocellular carcinoma, and the targeted treatment of this link is crucial. Capturing the optimal timing of treatment will bring more benefits to patients. In the field of liver fibrosis treatment, TCM has advantages that Western medicine fails to match, and proprietary Chinese medicines have made considerable achievements in this field, even entering the U.S. for Phase II clinical trials. Fu Zheng Hua Yu Tablet is a good example, which controls the disease by invigorating blood and eliminating blood stasis, benefiting essence and nourishing the liver, improving the body’s immunity, and improving liver microcirculation to inhibit the progression of liver fibrosis from several aspects. The main thing for fatty liver patients is to regulate their diet and exercise more. Control calorie intake, limit fat and carbohydrate intake, avoid spicy and stimulating food, combine work and rest, regular living, and regular medical checkups are essential.